insights_auto
Prečo akcie BNTX stúpli 5,32%?
Preskúmať podrobnejšiechevron_right
BNTX:NASDAQ
BioNTech
96,96 USD
arrow_upward
+5,32%(+4,90) 1 d.
96,96 USD
0,00% (0,00)
bedtimePo uzavretí
Zavreté: 9. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BNTX…
Otvoriť
92,45 USD
Vysoká
97,40 USD
Nízka
92,30 USD
Trh. kap.
24,36 mld.
Priem. obj.
993,50 tis.
Objem
1,32 mil.
Max. za 52 týž.
123,98 USD
Min. za 52 týž.
79,52 USD
Výnosy na akciu
-7,52 USD
Beta
1,22
Akcie v obehu
251,20 mil.
Počet zamestnancov
8 tis.
Otvoriť
92,45 USD
Vysoká
97,40 USD
Nízka
92,30 USD
Trh. kap.
24,36 mld.
Priem. obj.
993,50 tis.
Objem
1,32 mil.
Max. za 52 týž.
123,98 USD
Min. za 52 týž.
79,52 USD
Výnosy na akciu
-7,52 USD
Beta
1,22
Akcie v obehu
251,20 mil.
Počet zamestnancov
8 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Investing.com Nigeria
·
pred 6 hodinami
Form 4 BioNTech SE For: 9 October By Investing.com
Stock Titan
·
pred 10 hodinami
Under a trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 36,209 and 27,000 shares.
Benzinga
·
pred 12 hodinami
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Yahoo Finance
·
pred 15 hodinami
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Informácie o subjekte BioNTech